Empasiprubart
Highest phase reached
Phase 2
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Antibody
- Drug name
- Empasiprubart
- argx 117
- argx 117 rhuph20
- ARGX-117
- argx117
- ARGX117
- empasiprubart
- Empasiprubart
- empasiprubart [INN]
- EMPASIPRUBART [USAN]
- empasiprubart inn
- empasiprubart iv
- empasiprubart IV
- Empasiprubart IV
- empasiprubart usan
- Immunoglobulin G1 [235-alanine,236-alanine,434-lysine,435-phenylalanine], anti-(human complement component 2) (human monoclonal ARGX-117 γ1-chain), disulfide with human monoclonal ARGX-117 κ-chain, dimer
- immunoglobulin g1 235 alanine 236 alanine 434 lysine 435 phenylalanine anti human complement component 2 human monoclonal argx 117 γ1 chain disulfide with human monoclonal argx 117 κ chain dimer
- immunoglobulin g1 kappa anti homo sapiens c2 complement 2 humanized monoclonal antibody gamma1 heavy chain humanized 1 447 vh humanized homo sapiens ighv1 8 01 82 7 ighd ighj4 01 92 9 cdr imgt 8 8 11 26 33 51 58 97 107 1 118 homo sapiens ighg1 01 g1m17 1 g1v14 ch2 a1 3 a1 2 g1v46 ch3 k113 f114 ch1 k120 215 119 216 hinge 1 15 217 231 ch2 l1 3 a 235 l1 2 a 236 232 341 ch3 d12 357 l14 359 h113 k 434 n114 f 435 342 446 chs k2 del 447 119 447 221 218 disulfide with kappa light chain humanized 1 218 v kappa homo sapiens igkv4 1 01 74 3 igkj2 01 100 cdr imgt 10 3 9 27 36 54 56 93 101 1 111 homo sapiens igkc 01 100 km3 a45 1 157 v101 195 112 218 dimer 227 227 230 230 bisdisulfide produced in chinese hamster ovary cho cells cell line cho k1sv lacking the glutamine synthetase gs ko gene glycoform alfa
- immunoglobulin G1-kappa, anti-[Homo sapiens C2 (complement 2)], humanized monoclonal antibody; gamma1 heavy chain humanized (1-447) [VH humanized (Homo sapiens IGHV1-8*01 (82.7%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.11] (26-33.51-58.97-107)) (1-118) -Homo sapiens IGHG1*01, G1m17,1, G1v14 CH2 A1.3, A1.2, G1v46 CH3 K113, F114 (CH1 K120 (215) (119-216), hinge 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 D12 (357), L14 (359), H113>K (434), N114>F (435) (342-446), CHS K2>del (447)) (119-447)], (221-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV4-1*01 (74.3%) -IGKJ2*01 (100%), CDR-IMGT [10.3.9] (27-36.54-56.93-101)) (1'-111') -Homo sapiens IGKC*01 (100%), Km3, A45.1 (157), V101 (195) (112'-218')]; dimer (227-227'':230-230'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-K1SV lacking the glutamine synthetase (GS-KO) gene, glycoform alfa
- CAS registry numbers
- 2579031-19-7
- ChEMBL ID
- CHEMBL5314673
- FDA ingredient codes (UNII)
- PVA73UA67L
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Drug name stem
- -bart
- Condition
- Dermatomyositis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000398
- Subject identifier
- D003882
- Condition
- Virus Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000763
- Subject identifier
- D014777
- Condition
- Myositis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000783
- Subject identifier
- D009220
- Condition identifier
- EFO_0000398
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000763
- Condition identifier
- EFO_0000783
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005108
- Condition identifier
- MONDO_0006702
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007691
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009688
- Condition identifier
- MONDO_0016367
- Highest recorded phase
- 2
Trial references
- NCT06284954
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Heavy chain
- Type
- Protein
- Sequence
- EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALKFHYTQKSLSLSPG
- Component
- Disulfide bridges
- Sequence
- 22-96 $ 22''-96'' $ 23'-92' $ 23'''-92''' $ 138'-198' $ 138'''-198''' $ 227-227'' $ 230-230'' $ 145-201 $ 145''-201'' $ 221-218' $ 221''-218''' $ 262-322 $ 262''-322'' $ 368-426 $ 368''-426''
- Component
- Light chain
- Type
- Protein
- Sequence
- DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
- Component
- Glycosylation sites (N)
- Sequence
- 298 $ 298''
Related records
Trials (15)
- A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy
- A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy
- A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome
- A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- A Study to Assess the Absolute Bioavailability of Empasiprubart SC Administered With an Autoinjector and the Pharmacokinetic Noninferiority of Empasiprubart SC Versus Intravenous (IV) in Healthy Adult Participants
- A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy
- A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
- A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
- A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis
- ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
- SAD and MAD Study With IV and SC Doses of ARGX-117
In development for (5)
- Chronic inflammatory demyelinating polyradiculoneuropathy Phase 3
- Dermatomyositis Phase 2
- Guillain-Barre syndrome, familial Phase 3
- Myositis disease Phase 2
- Viral infectious disease Phase 2
Other linked conditions (1)
- Myasthenia gravis